Nifty
Sensex
:
:
23850.90
78782.24
-453.45 (-1.87%)
-606.82 (-0.76%)

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 543064 | NSE: SUVENPHAR

813.60
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  821.05
  •  821.05
  •  804.30
  •  814.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  217390
  •  1762.55
  •  1335.00
  •  542.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 33,706.95
  • 140.18
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 33,695.02
  • N/A
  • 15.98

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.10%
  • 11.08%
  • 9.76%
  • FII
  • DII
  • Others
  • 10.7%
  • 16.66%
  • 1.70%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 4.75
  • -7.31

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 1.07
  • -6.95

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 2.24
  • -12.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 31.97

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 8.73

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 28.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Net Sales
230.69
347.55
-33.62%
252.93
369.36
-31.52%
219.82
353.77
-37.86%
231.05
278.40
-17.01%
Expenses
150.76
179.80
-16.15%
179.59
197.49
-9.06%
154.68
207.08
-25.30%
133.09
178.52
-25.45%
EBITDA
79.93
167.75
-52.35%
73.34
171.86
-57.33%
65.14
146.70
-55.60%
97.96
99.88
-1.92%
EBIDTM
34.65%
48.27%
29.00%
46.53%
29.64%
41.47%
42.40%
35.88%
Other Income
18.16
10.67
70.20%
17.05
11.40
49.56%
14.34
13.01
10.22%
19.84
10.92
81.68%
Interest
1.60
1.86
-13.98%
2.30
5.03
-54.27%
1.27
1.38
-7.97%
0.50
0.29
72.41%
Depreciation
13.40
12.61
6.26%
17.25
12.02
43.51%
12.75
12.24
4.17%
11.89
12.03
-1.16%
PBT
83.09
163.95
-49.32%
70.85
166.21
-57.37%
65.47
146.08
-55.18%
105.41
98.48
7.04%
Tax
22.32
43.35
-48.51%
17.48
42.24
-58.62%
18.71
38.36
-51.23%
25.84
26.42
-2.20%
PAT
60.77
120.60
-49.61%
53.37
123.97
-56.95%
46.75
107.72
-56.60%
79.56
72.06
10.41%
PATM
26.34%
34.70%
21.10%
33.56%
21.27%
30.45%
34.43%
25.88%
EPS
2.39
4.74
-49.58%
2.10
4.87
-56.88%
1.84
4.23
-56.50%
3.13
2.83
10.60%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Net Sales
934.49
1,051.35
1,340.33
1,320.22
1,009.72
833.79
377.83
Net Sales Growth
-30.73%
-21.56%
1.52%
30.75%
21.10%
120.68%
 
Cost Of Goods Sold
277.36
311.39
402.97
394.05
297.56
225.32
101.46
Gross Profit
657.13
739.97
937.36
926.17
712.16
608.47
276.37
GP Margin
70.32%
70.38%
69.94%
70.15%
70.53%
72.98%
73.15%
Total Expenditure
618.12
645.54
766.17
738.50
566.72
449.03
206.28
Power & Fuel Cost
-
48.30
73.93
59.55
44.20
38.23
18.06
% Of Sales
-
4.59%
5.52%
4.51%
4.38%
4.59%
4.78%
Employee Cost
-
135.92
118.25
100.48
76.23
65.10
29.63
% Of Sales
-
12.93%
8.82%
7.61%
7.55%
7.81%
7.84%
Manufacturing Exp.
-
89.05
109.62
129.24
105.31
83.89
35.11
% Of Sales
-
8.47%
8.18%
9.79%
10.43%
10.06%
9.29%
General & Admin Exp.
-
35.90
33.87
28.99
27.73
25.97
12.62
% Of Sales
-
3.41%
2.53%
2.20%
2.75%
3.11%
3.34%
Selling & Distn. Exp.
-
10.35
17.64
19.80
10.53
9.43
6.72
% Of Sales
-
0.98%
1.32%
1.50%
1.04%
1.13%
1.78%
Miscellaneous Exp.
-
14.63
9.90
6.37
5.16
1.08
2.69
% Of Sales
-
1.39%
0.74%
0.48%
0.51%
0.13%
0.71%
EBITDA
316.37
405.81
574.16
581.72
443.00
384.76
171.55
EBITDA Margin
33.85%
38.60%
42.84%
44.06%
43.87%
46.15%
45.40%
Other Income
69.39
61.91
46.36
92.38
14.24
18.12
0.60
Interest
5.67
7.45
12.81
8.53
11.67
23.07
2.79
Depreciation
55.29
54.60
47.99
39.10
31.64
23.51
11.50
PBT
324.82
405.67
559.73
626.48
413.94
356.30
157.87
Tax
84.35
105.39
148.44
213.78
105.33
87.51
48.59
Tax Rate
25.97%
25.98%
26.52%
34.12%
25.45%
24.56%
30.78%
PAT
240.45
300.28
411.29
453.80
308.61
268.79
109.27
PAT before Minority Interest
240.45
300.28
411.29
453.80
308.61
268.79
109.27
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
25.73%
28.56%
30.69%
34.37%
30.56%
32.24%
28.92%
PAT Growth
-43.34%
-26.99%
-9.37%
47.05%
14.81%
145.99%
 
EPS
9.44
11.79
16.15
17.82
12.12
10.56
4.29

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Shareholder's Funds
2,050.66
1,735.18
1,527.18
1,180.81
844.76
590.29
Share Capital
25.46
25.46
25.46
25.46
12.73
0.00
Total Reserves
2,023.21
1,709.73
1,501.72
1,155.35
832.03
577.56
Non-Current Liabilities
96.53
71.79
92.11
73.91
127.68
35.12
Secured Loans
0.00
4.56
28.44
35.59
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
91.25
0.00
Long Term Provisions
10.50
8.30
8.89
6.65
8.31
5.95
Current Liabilities
206.06
303.09
347.52
321.51
319.85
190.67
Trade Payables
42.36
70.09
105.90
82.93
71.06
53.57
Other Current Liabilities
21.22
19.84
29.54
28.57
27.51
19.47
Short Term Borrowings
38.58
64.60
67.13
105.64
94.04
82.79
Short Term Provisions
103.90
148.56
144.94
104.36
127.24
34.83
Total Liabilities
2,353.25
2,110.06
1,966.81
1,576.23
1,292.29
816.08
Net Block
669.62
663.33
534.19
441.16
356.74
270.90
Gross Block
927.38
875.60
693.81
569.62
456.66
347.41
Accumulated Depreciation
257.76
212.27
159.62
128.46
99.91
76.51
Non Current Assets
990.90
954.70
701.66
909.68
781.17
393.28
Capital Work in Progress
179.08
165.09
29.99
96.32
101.71
111.07
Non Current Investment
130.58
117.10
117.10
361.19
307.46
0.07
Long Term Loans & Adv.
11.41
9.19
13.07
10.85
15.06
11.02
Other Non Current Assets
0.20
0.00
7.30
0.16
0.20
0.22
Current Assets
1,362.35
1,155.37
1,265.16
666.54
511.12
422.80
Current Investments
773.90
418.94
481.22
180.59
30.67
7.06
Inventories
231.20
312.81
283.42
201.08
174.87
157.10
Sundry Debtors
133.66
110.94
236.37
102.38
117.20
147.50
Cash & Bank
50.50
68.01
47.31
9.65
14.07
12.90
Other Current Assets
173.09
11.46
9.15
56.03
174.30
98.24
Short Term Loans & Adv.
161.19
233.21
207.69
116.80
134.56
37.32
Net Current Assets
1,156.29
852.28
917.64
345.04
191.27
232.13
Total Assets
2,353.25
2,110.07
1,966.82
1,576.22
1,292.29
816.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Cash From Operating Activity
358.48
457.20
330.00
382.55
406.92
50.40
PBT
405.67
559.73
667.59
467.67
404.51
157.87
Adjustment
15.35
37.46
40.63
36.48
34.60
13.93
Changes in Working Capital
47.41
5.77
-193.97
-12.17
54.21
-88.33
Cash after chg. in Working capital
468.43
602.96
514.26
491.98
493.33
83.47
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-109.95
-145.76
-184.26
-109.44
-86.41
-33.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-362.25
-195.01
-136.14
-311.40
-413.45
-65.48
Net Fixed Assets
-65.47
-154.01
-57.86
-107.57
-99.89
Net Investments
-374.60
-110.17
-173.65
-149.92
-269.19
Others
77.82
69.17
95.37
-53.91
-44.37
Cash from Financing Activity
-13.80
-241.95
-156.48
-75.66
7.32
25.98
Net Cash Inflow / Outflow
-17.57
20.24
37.38
-4.51
0.79
10.90
Opening Cash & Equivalents
64.80
44.56
7.18
11.70
10.90
0.00
Closing Cash & Equivalent
47.23
64.80
44.56
7.18
11.70
10.90

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Book Value (Rs.)
80.48
68.16
59.99
46.39
33.18
0.00
ROA
13.46%
20.18%
25.62%
21.52%
25.50%
13.39%
ROE
15.87%
25.21%
33.52%
30.47%
37.80%
18.92%
ROCE
21.22%
33.41%
45.92%
36.19%
44.55%
23.87%
Fixed Asset Turnover
1.17
1.71
2.09
1.97
2.07
1.09
Receivable days
42.46
47.25
46.80
39.69
57.94
142.49
Inventory Days
94.43
81.11
66.93
67.95
72.66
151.76
Payable days
65.90
79.70
87.45
94.44
49.88
86.75
Cash Conversion Cycle
70.98
48.66
26.27
13.19
80.72
207.50
Total Debt/Equity
0.02
0.04
0.06
0.12
0.22
0.14
Interest Cover
55.44
44.69
79.29
36.48
16.45
57.60

News Update:


  • Suven Pharmaceuticals’ arm gets EIR from USFDA for manufacturing facility
    9th Sep 2024, 18:00 PM

    The US FDA has categorized the inspection as Voluntary Action Indicated

    Read More
  • Suven Pharma - Quarterly Results
    9th Aug 2024, 15:34 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.